Inoxgen (Nitric Oxide)

Nitric oxide diffuses into the smooth muscle of pulmonary vessels, where it activates soluble guanylate cyclase. This enzyme raises cyclic GMP levels, causing relaxation of the vascular smooth muscle, reducing pulmonary vascular resistance, and enhancing gas exchange.

The dosage of Inoxgen is individualized; the prescribing clinician determines the concentration and duration based on patient response, hemodynamic monitoring, and arterial blood gases. No fixed regimen is provided here, as dosing must be tailored to each clinical situation.

Safety data for inhaled nitric oxide during pregnancy or lactation are limited. Use is generally reserved for situations where the potential benefit to the mother or fetus outweighs uncertain risks, and the decision should be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with agents such as phosphodiesterase‑5 inhibitors or prostacyclin analogues, inhaled nitric oxide offers rapid, selective pulmonary vasodilation with minimal systemic effects, allowing precise titration. However, it requires specialized delivery equipment and continuous monitoring, whereas alternative drugs may be administered systemically and have longer half‑lives.

Inoxgen cylinders should be stored at ambient temperature in a well‑ventilated, dry area away from heat sources, and protected from direct sunlight. Keep cylinders upright, secure them to prevent falling, and ensure that only trained personnel handle the gas using approved delivery systems.

Inoxgen is delivered via an endotracheopulmonary system, typically using a calibrated vaporizer or delivery circuit attached to a mechanical ventilator. The gas is inhaled directly into the airway, allowing rapid diffusion into the pulmonary vasculature. Administration is performed by qualified healthcare professionals under continuous hemodynamic and methemoglobin monitoring.

The most critical risks include severe methemoglobinemia, which can impair oxygen delivery, and rebound pulmonary hypertension that may occur after abrupt discontinuation. Significant hypotension and nitrogen dioxide formation can also lead to lung injury. Prompt detection through continuous monitoring and gradual weaning are essential to mitigate these hazards.

Inoxgen is contraindicated in patients with known hypersensitivity to nitric oxide, severe left‑ventricular dysfunction, or those who cannot be adequately monitored for methemoglobin levels. It should also be avoided in individuals with uncontrolled systemic hypotension or in settings lacking appropriate delivery and monitoring equipment.